ALK and non-small cell lung carcinoma: On the basis of these data, patients with EGFR- and ALK-mutated tumors were excluded from most randomized trials evaluating ICIs in combination with chemotherapy versus chemotherapy alone as frontline treatment for patients with advanced NSCLC.